Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 · New England Journal of Medicine · 3,605 citations
https://doi.org/10.1056/nejmoa032709
T
Thierry André
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.2K
Papers
64.2K
Citations
105
h-index
460
i10-index
Thierry André is an academic researcher from Inserm. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Genetic factors in colorectal cancer & Gastric Cancer Management and Outcomes. The author has an h-index of 105, co-authored 1034 publications.
ORCID: 0000-0002-5103-7095Papers by this author
worksPembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
2020 · New England Journal of Medicine · 2,821 citations
https://doi.org/10.1056/nejmoa2017699
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 · Journal of Clinical Oncology · 2,255 citations
https://doi.org/10.1200/jco.2008.20.6771
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
2018 · Journal of Clinical Oncology · 2,004 citations
https://doi.org/10.1200/jco.2017.76.9901
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
2010 · Journal of Clinical Oncology · 992 citations
https://doi.org/10.1200/jco.2009.27.6055
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
2022 · The Lancet Oncology · 842 citations
https://doi.org/10.1016/s1470-2045(22)00197-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat